Citation: | Jia Yanan, Zhu Jiqiao, Li Han, et al. Clinical application investigation of quantitative evaluation system of immune status in guiding individualized management of immunosuppressants after liver transplantation[J]. ORGAN TRANSPLANTATION, 2022, 13(6): 803-809. doi: 10.3969/j.issn.1674-7445.2022.06.017 |
[1] |
KONDA P, GOLAMARI R, EISEN HJ. Novel immunosuppression in solid organ transplantation[J]. Handb Exp Pharmacol, 2022, 272: 267-285. DOI: 10.1007/164_2021_569.
|
[2] |
DE MARTIN E, LONDOÑO MC, EMAMAULLEE J, et al. The optimal immunosuppression management to prevent early rejection after liver transplantation: a systematic review of the literature and expert panel recommendations[J]. Clin Transplant, 2022, DOI: 10.1111/ctr.14614[Epubaheadofprint].
|
[3] |
SHAKED A, DESMARAIS MR, KOPETSKIE H, et al. Outcomes of immunosuppression minimization and withdrawal early after liver transplantation[J]. Am J Transplant, 2019, 19(5): 1397-1409. DOI: 10.1111/ajt.15205.
|
[4] |
SHARMA P, SUN Y, NEAL J, et al. Renal outcomes of liver transplantation recipients receiving standard immunosuppression and early renal sparing immunosuppression: a retrospective single center study[J]. Transplant Direct, 2019, 5(9): e480. DOI: 10.1097/TXD.0000000000000917.
|
[5] |
OLSON JC. Immunosuppressive drugs and associated complications in abdominal organ transplantation[J]. Curr Opin Crit Care, 2022, 28(2): 208-215. DOI: 10.1097/MCC.0000000000000927.
|
[6] |
PINHEIRO RS, ANDRAUS W, ROMEIRO FG, et al. Model for establishing a new liver transplantation center through mentorship from a university with transplantation expertise[J]. PLoS One, 2022, 17(3): e0266361. DOI: 10.1371/journal.pone.0266361.
|
[7] |
BRUNET M, VAN GELDER T, ÅSBERG A, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report[J]. Ther Drug Monit, 2019, 41(3): 261-307. DOI: 10.1097/FTD.0000000000000640.
|
[8] |
CHARLTON M, LEVITSKY J, AQEL B, et al. International liver transplantation society consensus statement on immunosuppression in liver transplant recipients[J]. Transplantation, 2018, 102(5): 727-743. DOI: 10.1097/TP.0000000000002147.
|
[9] |
寇建涛, 李先亮, 朱继巧, 等. 自创免疫状态量化评分标准评估肝移植受者术后免疫状态的可行性分析[J]. 中华器官移植杂志, 2020, 41(6): 362-366. DOI: 10.3760/cma.j.cn421203-20191110-00407.
KOU JT, LI XL, ZHU JQ, et al. Application of Mingdao immune score system for evaluating the immune status of liver transplant recipients[J]. Chin J Organ Transplant, 2020, 41(6): 362-366. DOI: 10.3760/cma.j.cn421203-20191110-00407.
|
[10] |
李先亮, 贾亚男, 王若麟, 等. 创新免疫状态评估体系的建立及其在疾病诊疗中的应用[J]. 中国现代医学杂志, 2021, 31(16): 1-6. DOI: 10.3969/j.issn.1005-8982.2021.16.001.
LI XL, JIA YN, WANG RL, et al. Research progress in novel approaches to immune status evaluation and their application in clinical practice[J]. China J Mod Med, 2021, 31(16): 1-6. DOI: 10.3969/j.issn.1005-8982.2021.16.001.
|
[11] |
SHEN B, CEN Z, TAN M, et al. Current status of malignant tumors after organ transplantation[J]. Biomed Res Int, 2022: 5852451. DOI: 10.1155/2022/5852451.
|
[12] |
JUCAUD V, SHAKED A, DESMARAIS M, et al. Prevalence and impact of de novo donor-specific antibodies during a multicenter immunosuppression withdrawal trial in adult liver transplant recipients[J]. Hepatology, 2019, 69(3): 1273-1286. DOI: 10.1002/hep.30281.
|
[13] |
GILL RG, LIN CM. Linking innate immunity and chronic antibody-mediated allograft rejection[J]. Curr Opin Organ Transplant, 2019, 24(6): 694-698. DOI: 10.1097/MOT.0000000000000708.
|
[14] |
NEUBERGER J. Immunosuppression in gastroenterology and hepatology[J]. Best Pract Res Clin Gastroenterol, 2021, 54/55: 101758. DOI: 10.1016/j.bpg.2021.101758.
|
[15] |
DASHTI-KHAVIDAKI S, SAIDI R, LU H. Current status of glucocorticoid usage in solid organ transplantation[J]. World J Transplant, 2021, 11(11): 443-465. DOI: 10.5500/wjt.v11.i11.443.
|
[16] |
PONTICELLI C, GLASSOCK RJ. Prevention of complications from use of conventional immunosuppressants: a critical review[J]. J Nephrol, 2019, 32(6): 851-870. DOI: 10.1007/s40620-019-00602-5.
|
[17] |
REZAHOSSEINI O, MØLLER DL, KNUDSEN AD, et al. Use of T cell mediated immune functional assays for adjustment of immunosuppressive or anti-infective agents in solid organ transplant recipients: a systematic review[J]. Front Immunol, 2020, 11: 567715. DOI: 10.3389/fimmu.2020.567715.
|
[18] |
DI MAIRA T, LITTLE EC, BERENGUER M. Immunosuppression in liver transplant[J]. Best Pract Res Clin Gastroenterol, 2020, 46/47: 101681. DOI: 10.1016/j.bpg.2020.101681.
|
[19] |
MONDANELLI G, BIANCHI R, PALLOTTA MT, et al. A relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells[J]. Immunity, 2017, 46(2): 233-244. DOI: 10.1016/j.immuni.2017.01.005.
|
[20] |
BRAMI I, INI D, SASSONKER N, et al. Immunosuppressive drugs alter α1-antitrypsin production in hepatocytes: implications for epithelial gap repair[J]. Biol Blood Marrow Transplant, 2020, 26(4): 625-633. DOI: 10.1016/j.bbmt.2019.12.764.
|
[21] |
MARTIN-MORENO PL, TRIPATHI S, CHANDRAKER A. Regulatory T cells and kidney transplantation[J]. Clin J Am Soc Nephrol, 2018, 13(11): 1760-1764. DOI: 10.2215/CJN.01750218.
|
[22] |
PERNOT S, TERME M, RADOSEVIC-ROBIN N, et al. Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance[J]. Gastric Cancer, 2020, 23(1): 73-81. DOI: 10.1007/s10120-019-00983-3.
|
[23] |
HARTMANN FJ, BABDOR J, GHERARDINI PF, et al. Comprehensive immune monitoring of clinical trials to advance human immunotherapy[J]. Cell Rep, 2019, 28(3): 819-831. DOI: 10.1016/j.celrep.2019.06.049.
|
[24] |
KUMAR D, HUMAR A. CMV immune monitoring-where do we go from here?[J]. Am J Transplant, 2020, 20(8): 1961-1962. DOI: 10.1111/ajt.15875.
|
[25] |
SLOWIK V, LERRET SM, LOBRITTO SJ, et al. Variation in immunosuppression practices among pediatric liver transplant centers-society of pediatric liver transplantation survey results[J]. Pediatr Transplant, 2021, 25(2): e13873. DOI: 10.1111/petr.13873.
|
[26] |
BAKHTIYAR S, BATRA A, MALIK T, et al. Three decades' analysis of pediatric liver transplantation outcomes reveals limited long-term improvements[J]. Pediatr Transplant, 2022, 26(2): e14158. DOI: 10.1111/petr.14158.
|
[27] |
AKBULUT S, SAHIN TT. Comment on: acute rejection after liver transplantation is less common, but predicts better prognosis in HBV-related hepatocellular carcinoma patients[J]. Int J Surg Case Rep, 2021, 84: 106073. DOI: 10.1016/j.ijscr.2021.106073.
|
[28] |
HUSSAINI T, TURGEON RD, PARTOVI N, et al. Immunosuppression practices in liver transplantation: a survey of north American centers[J]. Exp Clin Transplant, 2018, 16(5): 550-553. DOI: 10.6002/ect.2017.0096.
|
[29] |
TASDOGAN BE, MA M, SIMSEK C, et al. Update on immunosuppression in liver transplantation[J]. Euroasian J Hepatogastroenterol, 2019, 9(2): 96-101. DOI: 10.5005/jp-journals-10018-1301.
|